Heavy Menstrual Bleeding in Women Treated with Direct Oral Anticoagulants: Results of the Prospective HEMBLED Registry

Abstract

Background

Heavy menstrual bleeding (HMB) is a common complication of anticoagulant therapy in menstruating women with venous thromboembolism (VTE). Direct oral anticoagulants (DOAC) used for VTE treatment may differ in their menstrual bleeding profiles. Therefore, the prospective multicenter noninterventional investigator-initiated HEMBLED registry (heavy menstrual bleeding in patients treated with DOAC) was performed to analyze spontaneous menstrual bleeding in women treated with therapeutic DOAC doses.

Methods

A modified pictorial blood assessment chart (PBAC) score was used to define the severity of menstrual bleeding. Patients were only included when they did not use hormonal or intrauterine contraception methods. The prospective follow-up was 4 months. The primary endpoint was the comparison of the PBAC scores between the individual DOAC groups.

Results

Overall, 73 patients with 213 monthly assessments of the PBAC scores were analyzed. Patients were on average 35 years old and were anticoagulated with apixaban (62%), rivaroxaban (26%), edoxaban (7%), or dabigatran (6%). The PBAC scores of the rivaroxaban group (mean: 145 points) were significantly increased by 54% compared with the apixaban group (mean: 93 points, p = 0.0193). HMB (PBAC score > 100 points) at least once was detected in 53% of the apixaban group compared with 79% of the rivaroxaban group (p = 0.0913). The duration of menstrual bleeding was numerically shorter in the apixaban group compared with the rivaroxaban group (p = 0.1894).

Conclusion

DOAC differ in their influence on the intensity of spontaneous menstrual bleeding. This should be taken into account when advising young women with VTE who need an oral anticoagulant.

Keywords

heavy menstrual bleeding - venous thrombosis - direct oral anticoagulants - rivaroxaban - apixaban

• References

• 1 de Jong CMM, Blondon M, Ay C. et al. Incidence and impact of anticoagulation-associated abnormal menstrual bleeding in women after venous thromboembolism. Blood 2022; 140 (16) 1764-1773
• 2 Kalmanti L, Lindhoff-Last E. Bleeding issues in women under oral anticoagulation. Hamostaseologie 2022; 42 (05) 337-347
• 3 Patel JP, Nzelu O, Roberts LN, Johns J, Ross J, Arya R. How do anticoagulants impact menstrual bleeding and quality of life? - the PERIOD study. Res Pract Thromb Haemost 2023; 7 (02) 100072
• 4 Själander A, Friberg B, Svensson P, Stigendal L, Lethagen S. Menorrhagia and minor bleeding symptoms in women on oral anticoagulation. J Thromb Thrombolysis 2007; 24 (01) 39-41
• 5 Myers B, Webster A. Heavy menstrual bleeding on rivaroxaban - comparison with apixaban. Br J Haematol 2017; 176 (05) 833-835
• 6 Eworuke E, Hou L, Zhang R. et al. Risk of severe abnormal uterine bleeding associated with rivaroxaban compared with apixaban, dabigatran and warfarin. Drug Saf 2021; 44 (07) 753-763
• 7 Corrales-Medina FF, Raffini L, Recht M, Santos J, Thornburg CD, Davila J. Direct oral anticoagulants in pediatric venous thromboembolism: experience in specialized pediatric hemostasis centers in the United States. Res Pract Thromb Haemost 2022; 7 (01) 100001
• 8 Azenkot T, Schwarz EB. Special considerations for women of reproductive age on anticoagulation. J Gen Intern Med 2022; 37 (11) 2803-2810
• 9 Weaver J, Shoaibi A, Truong HQ. et al. Comparative risk assessment of severe uterine bleeding following exposure to direct oral anticoagulants: a network study across four observational databases in the USA. Drug Saf 2021; 44 (04) 479-497
• 10 Beyer-Westendorf J, Michalski F, Tittl L, Hauswald-Dörschel S, Marten S. Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series. Lancet Haematol 2016; 3 (10) e480-e488
• 11 Godin R, Marcoux V, Tagalakis V. Abnormal uterine bleeding in women receiving direct oral anticoagulants for the treatment of venous thromboembolism. Vascul Pharmacol 2017; 93–95: 1-5
• 12 Higham JM, O'Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol 1990; 97 (08) 734-739
• 13 Rodeghiero F, Tosetto A, Abshire T. et al; ISTH/SSC joint VWF and Perinatal/Pediatric Hemostasis Subcommittees Working Group. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost 2010; 8 (09) 2063-2065
• 14 Spence M, de Repentigny K, Bowman M, Hopman W, Thibeault L, James P. Validation of the pictorial blood loss assessment chart using modern sanitary products. Haemophilia 2021; 27 (05) e632-e635
• 15 De Crem N, Peerlinck K, Vanassche T. et al. Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists. Thromb Res 2015; 136 (04) 749-753
• 16 Ferreira M, Barsam S, Patel JP. et al. Heavy menstrual bleeding on rivaroxaban. Br J Haematol 2016; 173 (02) 314-315
• 17 Moldenhauer A, Hellstern P, Hoffmann T, Fischer JC. Gender-associated variation in DOAC levels. Clin Lab 2023 69. (07)
• 18 Martinelli I, Lensing AW, Middeldorp S. et al. Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. Blood 2016; 127 (11) 1417-1425
• 19 Huisman MV, Ferreira M, Feuring M, Fraessdorf M, Klok FA. Less abnormal uterine bleeding with dabigatran than warfarin in women treated for acute venous thromboembolism. J Thromb Haemost 2018; 16 (09) 1775-1778
• 20 Scheres L, Brekelmans M, Ageno W. et al. Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study. BJOG 2018; 125 (12) 1581-1589
• 21 Grandone E, Mastroianno M, Pacilli G. et al. Blood loss in women of childbearing potential taking oral anticoagulants for venous thromboembolism (the BLEED study). Thromb Haemost 2025; 125 (06) 523-532